CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Flunarizine 5mg +1 moredrug
Likely dose
Flunarizine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04064814
NCT04064814Phase 4Completed

Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population: A Randomized Controlled Trial

All India Institute of Medical Sciences, Bhubaneswar·interventional·Posted Aug 22, 2019·Updated Jul 25, 2023

In Brief

A Phase 4 clinical trial evaluating Flunarizine 5mg and Alpha lipoic acid 300mg for Adolescent Migraine. Completed, enrolled 60 participants across 1 site.

Detailed Summary

Migraine causes a substantial impact on the physical and mental health of a child and it is a major cause for time-off school leading to impaired academic performance. Therefore prophylactic treatment is suggested for adolescents with frequent or disabling migraine, aiming at improving the function, quality of life and reducing disability. The most commonly used non-pharmacological agents for the prophylactic management of migraine in adolescents are nutraceuticals. Amongst all nutraceuticals, most commonly used agents for prophylaxis are coenzyme Q10, magnesium, riboflavin, feverfew and butterbur . Alpha-lipoic acid (ALA) or 6,8-thioctic acid, is an endogenous molecule which functions as an important co-factor for various enzyme complexes in mitochondria and plays an important role in energy metabolism.ALA is a nutraceutical agent which also has neuroprotective and anti-inflammatory effects. It has been proved that the thiol level remains low in migraine patients. However, only one study has been done by Ali et al in the pediatric population where the combination of ALA and topiramate has shown promising results but the study result is not generalizable due to its inherent limitations. So, the study has been planned with an aim to evaluate the efficacy and safety of ALA as add-on therapy with flunarizine in the adolescent age group

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIndia
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedAug 22, 2019
Enrollment StartSep 14, 2019
Primary CompletionApr 30, 2021
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.9 years ago

Interventions

Flunarizine 5mgdrug

Flunarizine 5mg once daily,orally for 12 weeks

Alpha lipoic acid 300mgdrug

Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks